2037 Delayed contrast enhancement cardiac magnetic resonance imaging IN trastuzumab induced cardiomyopathy
© Jassal et al; licensee BioMed Central Ltd. 2008
Published: 22 October 2008
Trastuzumab (Herceptin), an antagonist to the human epidermal growth factor 2 (HER2) receptor, significantly decreases the rates of breast cancer recurrence and mortality by 50%. Despite therapeutic benefits, the risk of cardiotoxicity with Trastuzumab ranges from 10–15% when administered in combination with anthracyline therapy. Although serial multiple gated acquisition scans are widely used to monitor cardiac dysfunction in breast cancer patients, cardiac MRI (CMR) is becoming the gold standard for the non-invasive assessment of left ventricular (LV) systolic dysfunction in dilated cardiomyopathies.
To describe the utility of CMR in the assessment of Trastuzumab induced cardiomyopathy.
Between 2005–2006 inclusive, 160 breast cancer patients who received Trastuzamab in addition to anthracyline based adjuvant therapy were identified at a tertiary care oncology centre. Of the total population, 20 patients were identified with Trastuzumab induced cardiomyopathy based on LV ejection fraction (EF) less than 40% on either serial MUGA or echocardiography. Cardiac MRI was performed on all 20 patients using a 1.5 T scanner to determine LV volumes and systolic function. Delayed-enhancement inversion recovery CMR (DE-CMR) was performed after 10 minutes of 0.2 mmol/kg injection of Gadolinium in all patients to assess scar formation.
DE-CMR is a novel way of detecting early changes in the myocardium due to Trastuzumab induced cardiotoxicity. Future studies are required to validate identification of positive delayed enhancement using CMR as a subclinical marker for future LV dysfunction in this select population.
This article is published under license to BioMed Central Ltd.